Breaking News: Promising Phase II Results
Clinical Stage Biotech
NovelMed Therapeutics
We plan to lead the complement blockers market through our strong intellectual property, trade-secrets and know-how.
Breaking News: Promising Phase II Results
We plan to lead the complement blockers market through our strong intellectual property, trade-secrets and know-how.
The company's mission is to address the unmet needs of patients suffering from these debilitating conditions, providing them with novel treatment options that improve their quality of life.
NovelMed’s strategy to selectively target the Alternative Pathway has led to the development of several first-in-class antibody-based drugs that have shown promising results in Phase II clinical trials. We believe we can lead the rare disease market based on our superior mechanism of action and our efficient development strategy.
Our early Phase II proof-of-concept results for PNH patients are promising. The next steps of our development strategy include
Copyright © 2024 NovelMed Therapeutics - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.